Lyell Immunopharma, Inc.
LYEL
$0.5854
-$0.0209-3.45%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -330.51% | 2.68% | 24.49% | -14.62% | -4.08% |
| Total Depreciation and Amortization | 7.39% | -4.51% | -2.45% | -0.65% | -0.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3,551.49% | 1.49% | -77.66% | 205.73% | -2.15% |
| Change in Net Operating Assets | -96.72% | 208.70% | 70.53% | -287.98% | -29.02% |
| Cash from Operations | -34.82% | 8.01% | 9.33% | -3.40% | -7.83% |
| Capital Expenditure | 25.42% | 82.18% | -1,003.33% | -20.00% | 87.18% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4,194.13% | -95.64% | 105.86% | 121.88% | -200.80% |
| Cash from Investing | 2,689.62% | -95.74% | 104.63% | 121.84% | -201.02% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | 736.89% | -88.32% | 1,125.00% |
| Repurchase of Common Stock | -- | -- | 100.00% | 38.21% | 42.79% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -100.00% | 3,092.59% | -96.44% | 630.77% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 120.23% | -526.03% | 138.88% | 85.78% | -327.29% |
